Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.

ABSTRACT:

Aim

To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of non-alcoholic steatohepatitis (NASH).

Methods

Twelve patients with biopsy-proven NASH were randomized to sitagliptin (100 mg daily) (n = 6) or placebo (n = 6) for 24 wk. The primary outcome was improvement in liver fibrosis after 24 wk. Secondary outcomes included evaluation of changes in NAFLD activity score (NAS), individual components of NAS (hepatocyte ballooning, lobular inflammation, and steatosis), glycemic control and insulin resistance [including measurements of glycated hemoglobin (HbA1C) and adipocytokines], lipid profile including free fatty acids, adipose distribution measured using magnetic resonance imaging (MRI), and thrombosis markers (pla

SUBMITTER: Joy TR 

PROVIDER: S-EPMC5221278 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature